FDA Grants Accelerated Approval to Repotrectinib for NTRK Fusion–Positive Solid Tumors
Today, the FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTR…